European neuro-oncology quality assessment (ENOQUA): A European organization for the research and treatment of cancer (EORTC) brain tumor group research project
Year: 2025
Type: article
Study design: Observational Study
Abstract: AbstractAbstract Background The care of patients with brain tumors is a complex task that requires quality standards and quality assurance indicators. In the present study, several quality indicators were evaluated in routine clinical care. Methods The EORTC Brain Tumor Group (BTG) developed quality indicators from published guidelines and tested them in 19 BTG sites across Europe. Each site extracted data from the files of 20 randomly selected glioblastoma patients diagnosed in 2018. Associations between quality indicators, site characteristics and median overall survival (mOS) were examined. Results A total of 364 patient files were evaluated at 19 sites. Excellent compliance was observed in the documentation of neuropathology report with isocitrate dehydrogenase (IDH) status (92.0%), O6-methylguanine DNA methyltransferase promoter methylation (MGMT) status (78.0%), multidisciplinary case discussion (95.3 %), extent of resection (87.1%), and radiotherapy details (96.9%) as well as consent to chemotherapy (75.5%). Performance was not as good for early postoperative MRI (67.2%), psycho-oncological care (40.5%), avoiding antineoplastic therapy in the last weeks of life (63.1%) and early referral to palliative services (23.5%). Timely start of radiotherapy (P = .0153), the presence of a radiotherapy report in the medical record (P = .0077), and patient education on oral chemotherapy (P = .0002) were positively associated with mOS, while early referral to palliative care was associated with shorter mOS (P < .0001). Conclusions The quality indicators tested in this research project performed with some variability between sites. Significant associations between individual quality indicators and mOS were observed. The proposed quality indicators should be validated prospectively.
Source: Neuro-Oncology Practice
DOI: 10.1093/nop/npaf103
Authors: Evangelia Razis, Thierry Gorlia, Matthias Preusser, Jean-François Daisne, Ludo Vanopdenbosch, Patrick Roth, Maximilian J Mair, Markus Wolfram Gross, Vittoria Espeli, Tomas Kazda, Jordi Bruna, Andrea Di Cristofori, Giuseppe Lombardi, Egils Valeinis, Dieta Brandsma, Annika Malmstrom, Petter Brandal, Ana Azevedo, Naureen Keric, Philipp Lohmann, Anastasia Vernadou, Brigitta Gertrud Baumert, Nicolaus Andratschke, Michael Weller, Filip de Vos, Peter Hau
Institutions: Hygeia Hospital, European Organisation for Research and Treatment of Cancer, Medical University of Vienna, KU Leuven, AZ Sint-Jan, University of Zurich, University Hospital Zurich, University of Basel, University Hospital of Basel, Ente Ospedaliero Cantonale, Istituto Oncologico della Svizzera Italiana, Masaryk Memorial Cancer Institute, Bellvitge University Hospital, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Istituto Oncologico Veneto, Pauls Stradiņš Clinical University Hospital, The Netherlands Cancer Institute, Linköping University, Oslo University Hospital, Instituto Português de Oncologia Francisco Gentil, University Medical Center of the Johannes Gutenberg University Mainz, Forschungszentrum Jülich, Universitätsklinikum Aachen, RWTH Aachen University, Kantonsspital Graubünden, University Medical Center Utrecht, University Hospital Regensburg, University of Regensburg
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4415066262